Pamela Kunz, MD, Named Editor-in-Chief of New JCO Oncology Advances

For immediate release
January 30, 2024


Naomi Hagelund

ALEXANDRIA, Va. – The American Society of Clinical Oncology (ASCO) announces the upcoming launch of JCO Oncology Advances (JCO OA), a new open-access and interdisciplinary journal. We are excited to name Pamela Kunz, MD, as the new Editor-in-Chief of this innovative journal dedicated to accelerating progress in the global fight against cancer by providing a platform where innovation in cancer research meets accessibility.  

"We are thrilled to welcome Dr. Kunz to lead JCO Oncology Advances," said ASCO President Lynn Schuchter, MD, FASCO. "Her extensive expertise in medical oncology and vision for integrating scientific research with clinical care align perfectly with the mission of JCO OA. This new journal is a testament to ASCO's commitment to advancing cancer care.” 

Dr. Kunz, leading the Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center, brings much experience to this role. She is also the Division Chief of GI Medical Oncology at Yale.  She serves as an Associate Professor of Internal Medicine, specializing in Medical Oncology, at the Yale School of Medicine. Her academic and professional journey, from the Geisel School of Medicine at Dartmouth to her leadership roles at Yale, makes her an ideal choice to spearhead this initiative. 

Under Dr. Kunz's leadership, JCO OA is committed to fostering interdisciplinary collaboration and making cutting-edge oncological insights freely accessible, supporting the global effort to improve patient outcomes. 

“Leading as the first Editor-in-Chief of JCO Oncology Advances, I am committed to shaping this platform into the foremost oncology open-access journal. By publishing a wide array of content, we aim to engage a diverse audience, encompassing academics, community practitioners, international colleagues, and patient partners,” said Dr. Kunz. “Our accessible online format empowers us to be innovative, agile, and impactful, extending our reach far beyond conventional boundaries.” The journal will open for submissions in Spring of 2024. Learn more about Dr. Kunz and JCO Oncology Advances. 

About the JCO Family of Journals: 
ASCO’s publications—including the Society’s flagship publication, the Journal of Clinical Oncology—serve readers as the most credible, authoritative, peer-reviewed resources for significant clinical oncology research that informs the delivery of high-quality patient care across the globe. 

About ASCO: 

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to the principle that knowledge conquers cancer. Together with the Association for Clinical Oncology, ASCO represents nearly 50,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of high quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Conquer Cancer, the ASCO Foundation, supports ASCO by funding groundbreaking research and education across cancer’s full continuum. Learn more at, explore patient education resources at www.Cancer.Net, and follow us on FacebookTwitterLinkedIn, Instagram, and YouTube.